


**In the Claims:**

1. (previously submitted) A compound of the formula (I)



wherein,

- R1 is hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,
- R2 is hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms or OH,
- R3 is hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms or OH,
- Ar is 7H-pyrrolo-[2,3-d]-pyrimidine, which may be linked via any of its positions and which is substituted in at least one of its positions by alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, nitro, NRaRb, alkylcarbonylamino having 1, 2, 3 or 4 carbon atoms, hydroxyl, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms, S(O)<sub>n</sub>R4, CO<sub>2</sub>H, alkoxycarbonyl having 1, 2, 3, 4, 5 or 6 carbon atoms, alkylcarbonyl having 1, 2, 3, 4, 5 or 6 carbon atoms, CONRaRb, CN, polyfluoroalkyl having 1, 2, 3 or 4 carbon atoms, polyfluoroalkoxy having 1, 2 or 3 carbon atoms or SO<sub>3</sub>H,

n = 0, 1 or 2,

Ra and Rb

are independently of each other hydrogen, linear or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or Ra and Rb form, together with the nitrogen atom to which they are attached, a 5- or 6-membered heterocycle, which may optionally contain another hetero atom chosen from O, S and N,

- R4 is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, alkylamino having 1, 2, 3, 4, 5 or 6 carbon atoms or NH<sub>2</sub>,
- or a racemic mixture, enantiomer, diastereomer, or tautomer of such compound, or a mixture thereof, or a pharmaceutically acceptable salt of such compound, racemic mixture, enantiomer, diastereomer, tautomer, or mixture.

2. (cancelled)

3. (previously submitted) A compound according to claim 1 wherein:

Ar is 4-(7H-pyrrolo-[2,3-d]-pyrimidinyl), which is substituted in at least one of its positions by alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, nitro, NRaRb, alkylcarbonylamino having 1, 2, 3 or 4 carbon atoms, hydroxyl, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms, S(O)<sub>n</sub>R<sub>4</sub>, CO<sub>2</sub>H, alkoxycarbonyl having 1, 2, 3, 4, 5 or 6 carbon atoms, alkylcarbonyl having 1, 2, 3, 4, 5 or 6 carbon atoms, CONRaRb, CN, polyfluoroalkyl having 1, 2, 3 or 4 carbon atoms, polyfluoroalkoxy having 1, 2 or 3 carbon atoms or SO<sub>3</sub>H<sup>-</sup>.

4. (previously submitted) A compound according to claim 1 which is 3-Guanidinocarbonyl-1-(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-indole, or a tautomer thereof or a pharmaceutically acceptable salt of such compound or tautomer.

5-19 (cancelled)


20. (original) A diagnostic agent comprising a compound according to claim 1.

21-32 (cancelled)

33. (original) A diagnostic agent comprising a compound according to claim 1 in combination with an another medicament or active ingredient.

34-47 (cancelled)

48. (previously submitted) A process for the preparation of a compound according to claim 1,  
comprising



a) reacting a heteroaryl halide ArX of the formula (VI) with a 3-alkoxycarbonyl-1H-indole of the formula (II);

b) saponifying the obtained 3-alkoxycarbonyl-1-heteroaryl-indole of the formula (III);

c) converting the obtained 3-carboxy-1-heteroaryl-indole of the formula (IV) to the corresponding acid chloride of the formula (V);

d) reacting the acid chloride of formula (V) with guanidine, and

isolating the compound according to claim 1; and optionally converting it into a pharmaceutically acceptable salt thereof,

wherein in the compounds of the formula II, III, IV, V and VI

Ar and R<sub>1</sub> to R<sub>3</sub> are defined as in claim 1,

X is F, Cl, Br or I and

R is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.